Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of a quadrivalent split influenza virus vaccine in infants aged 6–35 months
CTR20232941Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza virus vaccine, quadrivalent, split virus in influenza, sponsored by Sinovac Biotech Ltd.. Started Sep 2023; status: completed.
02
Drugs
influenza virus vaccine, quadrivalent, split virus
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20232941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232941.